Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Clin Oncol. 2012 Feb 1;30(4):461; author reply 461-2. doi: 10.1200/JCO.2011.40.2305. Epub 2011 Dec 27.

Paclitaxel, not bevacizumab, was primarily responsible for the favorable effects seen in the RIBBON-2 trial.

Comment on

PMID:
22203773
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk